|
|
||||||||||
|
J Am Coll Cardiol, 2006; 48:761-764, doi:10.1016/j.jacc.2006.04.076
(Published online 21 July 2006). © 2006 by the American College of Cardiology Foundation |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||


* Mayo Clinic, Rochester, Minnesota
University of California, San Francisco, California
Yale University, New Haven, Connecticut
Manuscript received January 27, 2006; revised manuscript received March 20, 2006, accepted April 4, 2006.
* Reprint requests and correspondence: Dr. Todd D. Miller, Mayo Clinic, Gonda 5-412, 200 First Street, SW, Rochester, Minnesota 55901 (Email: miller.todd{at}mayo.edu).
Given the elevated risk of cardiovascular events and the higher prevalence of silent coronary artery disease (CAD) in diabetic versus non-diabetic patients, screening asymptomatic diabetic patients for CAD is an appealing concept. However, many factors argue against implementing a broad-based screening program at the present time. Foremost is the lack of any published data demonstrating that a prospectively applied screening program improves outcome in asymptomatic diabetic patients. The true prevalence of CAD, and in particular prognostically important CAD, in this population is uncertain. Consensus documents recommend more aggressive treatment of hypertension and hyperlipidemia solely on the basis of diabetes status, without differentiation based on the presence or absence of identifiable CAD. There is no evidence that use of anti-ischemic medication can alter the natural history of CAD in these patients. Retrospectively performed studies using stress single-photon emission computed tomography (SPECT) imaging have reported that approximately 50% and 20% of patients have abnormal and high-risk images, respectively. However, the only prospectively designed study, the DIAD (Detection of Ischemia in Asymptomatic Diabetics) study, reported a much lower percentage of abnormal SPECT images (16%) and images with a very large (
10% of the left ventricle) defect (1%). The financial implications of screening all asymptomatic diabetic patients determined to be at intermediate and high risk by clinical scoring systems is enormous. Clearly more data are needed to address this issue. Future studies should consider possible methods to enrich the patient subset that might benefit from screening and should include carefully performed cost-effective analyses.
| ||||||||||
This article has been cited by other articles:
![]() |
A.J.H.A. Scholte, J.D. Schuijf, M.P. Stokkel, A. de Roos, and J.J. Bax The Difficulty of Adequate Risk Stratification for Patients With Asymptomatic Diabetes Circulation, July 15, 2008; 118(3): e65 - e68. [Full Text] [PDF] |
||||
![]() |
G. A. Diamond, S. Kaul, and P. K. Shah Screen Testing: Cardiovascular Prevention in Asymptomatic Diabetic Patients J. Am. Coll. Cardiol., May 15, 2007; 49(19): 1915 - 1917. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. A. Beller Noninvasive Screening for Coronary Atherosclerosis and Silent Ischemia in Asymptomatic Type 2 Diabetic Patients: Is it Appropriate and Cost-Effective? J. Am. Coll. Cardiol., May 15, 2007; 49(19): 1918 - 1923. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J. Bax, S. E. Inzucchi, R. O. Bonow, J. D. Schuijf, M. R. Freeman, E. J. Barrett, and on behalf of the Global Dialogue Group for the Eva Cardiac Imaging for Risk Stratification in Diabetes Diabetes Care, May 1, 2007; 30(5): 1295 - 1304. [Full Text] [PDF] |
||||
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |